ARCpoint（ARC）株式概要ARCpoint Inc.は、米国で薬物、アルコール、DNA、臨床検査、スクリーニングサービスを提供するフランチャイズシステムを提供しています。 詳細ARC ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析キャッシュランウェイが1年未満である 過去5年間で収益は年間15.8%減少しました。 収益が 100 万ドル未満 ( $606K )株式の流動性は非常に低い +2 さらなるリスクすべてのリスクチェックを見るARC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.012.8k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-9m19m2016201920222025202620282031Revenue US$39.2kEarnings US$2.8kAdvancedSet Fair ValueView all narrativesARCpoint Inc. 競合他社Jack Nathan MedicalSymbol: TSXV:JNHMarket cap: CA$871.0kJustera HealthSymbol: CNSX:VTALMarket cap: CA$1.2mGlobal Health ClinicsSymbol: CNSX:MJRXMarket cap: CA$563.5kNewtopiaSymbol: TSXV:NEWUMarket cap: CA$866.3k価格と性能株価の高値、安値、推移の概要ARCpoint過去の株価現在の株価CA$0.0152週高値CA$0.0852週安値CA$0.005ベータ-21ヶ月の変化0%3ヶ月変化0%1年変化-84.62%3年間の変化-95.24%5年間の変化n/aIPOからの変化-98.00%最新ニュースお知らせ • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.Reported Earnings • Mar 05Full year 2025 earnings released: US$0.017 loss per share (vs US$0.013 profit in FY 2024)Full year 2025 results: US$0.017 loss per share (down from US$0.013 profit in FY 2024). Revenue: US$605.7k (down 89% from FY 2024). Net loss: US$2.12m (down 256% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.3m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-US$7.5m). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (CA$1.28m market cap, or US$918.6k). Minor Risk Revenue is less than US$5m (US$1.5m revenue).Reported Earnings • Nov 30Third quarter 2025 earnings released: US$0.004 loss per share (vs US$0.051 profit in 3Q 2024)Third quarter 2025 results: US$0.004 loss per share (down from US$0.051 profit in 3Q 2024). Revenue: US$113.7k (down 91% from 3Q 2024). Net loss: US$507.2k (down 110% from profit in 3Q 2024).Reported Earnings • Aug 27Second quarter 2025 earnings released: US$0.006 loss per share (vs US$0.015 loss in 2Q 2024)Second quarter 2025 results: US$0.006 loss per share (improved from US$0.015 loss in 2Q 2024). Net loss: US$704.2k (loss narrowed 50% from 2Q 2024).お知らせ • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.最新情報をもっと見るRecent updatesお知らせ • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.Reported Earnings • Mar 05Full year 2025 earnings released: US$0.017 loss per share (vs US$0.013 profit in FY 2024)Full year 2025 results: US$0.017 loss per share (down from US$0.013 profit in FY 2024). Revenue: US$605.7k (down 89% from FY 2024). Net loss: US$2.12m (down 256% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.3m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-US$7.5m). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (CA$1.28m market cap, or US$918.6k). Minor Risk Revenue is less than US$5m (US$1.5m revenue).Reported Earnings • Nov 30Third quarter 2025 earnings released: US$0.004 loss per share (vs US$0.051 profit in 3Q 2024)Third quarter 2025 results: US$0.004 loss per share (down from US$0.051 profit in 3Q 2024). Revenue: US$113.7k (down 91% from 3Q 2024). Net loss: US$507.2k (down 110% from profit in 3Q 2024).Reported Earnings • Aug 27Second quarter 2025 earnings released: US$0.006 loss per share (vs US$0.015 loss in 2Q 2024)Second quarter 2025 results: US$0.006 loss per share (improved from US$0.015 loss in 2Q 2024). Net loss: US$704.2k (loss narrowed 50% from 2Q 2024).お知らせ • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.Reported Earnings • May 28First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: US$177.4k (down 89% from 1Q 2024). Net loss: US$633.5k (loss narrowed 57% from 1Q 2024).New Risk • May 08New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Negative equity (-US$6.6m). Market cap is less than US$10m (CA$11.6m market cap, or US$8.37m). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (26% increase in shares outstanding).お知らせ • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.お知らせ • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (50% average weekly change). Negative equity (-US$6.1m). Earnings have declined by 65% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (CA$9.43m market cap, or US$6.58m).お知らせ • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.Reported Earnings • Nov 29Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.016 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.051 (up from US$0.016 loss in 3Q 2023). Revenue: US$1.22m (down 24% from 3Q 2023). Net income: US$5.19m (up US$6.64m from 3Q 2023).Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: US$1.65m (up 8.8% from 2Q 2023). Net loss: US$1.40m (loss narrowed 40% from 2Q 2023).お知らせ • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.お知らせ • Jul 06ARCpoint Inc. announced that it expects to receive CAD 1.5 million in fundingARCpoint Inc. announced a non-brokered private placement to issue up to 20,000,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,500,000 on July 5, 2024. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange.Reported Earnings • Apr 30Full year 2023 earnings releasedFull year 2023 results: Revenue: US$6.67m (down 39% from FY 2022). Net loss: US$8.66m (loss widened 7.7% from FY 2022).Board Change • Mar 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Roger He was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Jan 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$7.2m). Revenue has declined by 60% over the past year. Market cap is less than US$10m (CA$11.0m market cap, or US$8.18m). Minor Risk Shareholders have been diluted in the past year (12% increase in shares outstanding).お知らせ • Jan 23ARCpoint Inc. announced that it has received $1.1 million in fundingOn January 22, 2024, ARCpoint Inc. closed the transaction. The company has now issued 11,000,000 Class A subordinate voting shares at a price of $0.10 per share for the gross proceeds of $1,100,000. Certain insiders of the company purchased or acquired direction or control over a total of 4,000,000 shares as part of the Offering.お知らせ • Jan 04ARCpoint Inc. announced that it expects to receive $1.6 million in fundingARCpoint Inc. announced a non-brokered private placement of up to 16,000,000 subordinated voting common shares at a price of $0.10 per share for the gross proceeds of $1,600,000 on January 2, 2024. The company anticipates that certain directors, officers and insiders of the company will purchase shares in an aggregate amount of up to $450,000 under the offering, The offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.Reported Earnings • Nov 24Third quarter 2023 earnings released: US$0.016 loss per share (vs US$11.81 loss in 3Q 2022)Third quarter 2023 results: US$0.016 loss per share (improved from US$11.81 loss in 3Q 2022). Revenue: US$1.61m (down 5.8% from 3Q 2022). Net loss: US$1.45m (loss narrowed 18% from 3Q 2022).Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.026 loss per share (vs US$6.90 loss in 2Q 2022)Second quarter 2023 results: US$0.026 loss per share. Revenue: US$1.52m (down 33% from 2Q 2022). Net loss: US$2.34m (loss widened 127% from 2Q 2022).お知らせ • Jul 12Arcpoint Inc. Launches MyARCpointLabsARCpoint Inc. reported that it has launched its new consumer e-commerce platform, MyARCpointLabs. MyARCpointLabs was developed to make it easier for both the Company's franchisees to attract and better serve individual healthcare consumers and for consumers to more easily purchase the Company's products and services. ARCpoint's goal is to leverage technology along with brick-and-mortar locations to give consumers access to convenient, cost-effective healthcare information and solutions with transparent, up-front pricing, so that they can be proactive and preventative with their health and well-being. By combining an easy-to-use consumer mobile platform with intuitive digital marketing and scheduling tools, MAPL will help close a growing gap within the healthcare system by delivering preventative healthcare solutions to all those who want them.Reported Earnings • May 20First quarter 2023 earnings released: US$0.023 loss per share (vs US$4.64 profit in 1Q 2022)First quarter 2023 results: US$0.023 loss per share (down from US$4.64 profit in 1Q 2022). Revenue: US$1.71m (down 69% from 1Q 2022). Net loss: US$2.03m (down 393% from profit in 1Q 2022).お知らせ • May 16Arcpoint Inc. Announces Appointment of Mr. Bob Mann as President of Arcpoint FranchiseARCpoint Inc. announced that Mr. Bob Mann has been appointed President of ARCpoint Franchise Group LLC (AFG), a wholly owned US subsidiary of the Company that operates ARCpoints franchise business. Mr. Mann comes to AFG with over 20 years of successful leadership and innovation experience including 15 years in the US diagnostic services space. He will be responsible for driving both top line growth at all franchisee locationsand growing the Companys distribution network from the current 134 locations. Mr. Mann started his diagnostics career at Quest Diagnostics in 2006 as a Sales Manager for Quests NC and SC sales teams before taking on different roles including: leading new business acquisition, developing strategiesfor growth and working with health plans and large healthcare entities. In 2012, he joined Cordant Health Solutions, then known as Sterling Healthcare, which went on to acquire five laboratories and six pharmacies to grow into one of the leading toxicology labs and behavioral health pharmacies in the US. For the past 8 years, Mr. Mann served as part of Cordants Executive Leadership team and held several key roles, including as Executive Vice President of Cordants Integrated Services group and overseeing sales and strategy. He was instrumental in the development of many of Cordants strategic toxicology and pharmacy offerings and also led the development of Cordants novel behavioral health pharmacy program that integrated laboratory and pharmacy services.Reported Earnings • Apr 15Full year 2022 earnings released: US$0.10 loss per share (vs US$38.48 profit in FY 2021)Full year 2022 results: US$0.10 loss per share (down from US$38.48 profit in FY 2021). Revenue: US$10.9m (down 43% from FY 2021). Net loss: US$8.04m (down 240% from profit in FY 2021).Buying Opportunity • Dec 10Now 31% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be CA$0.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only.お知らせ • Nov 16+ 1 more updateARCpoint Inc. to Report Q3, 2022 Results on Nov 28, 2022ARCpoint Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 28, 2022Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Mark Orsmond was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元ARCCA HealthcareCA 市場7D0%1.0%1.5%1Y-84.6%28.7%33.7%株主還元を見る業界別リターン: ARC過去 1 年間で28.7 % の収益を上げたCanadian Healthcare業界を下回りました。リターン対市場: ARCは、過去 1 年間で33.7 % のリターンを上げたCanadian市場を下回りました。価格変動Is ARC's price volatile compared to industry and market?ARC volatilityARC Average Weekly Movementn/aHealthcare Industry Average Movement5.9%Market Average Movement10.2%10% most volatile stocks in CA Market18.0%10% least volatile stocks in CA Market3.9%安定した株価: ARCの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のARCのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト1998n/aJohn Constantinewww.arcpointlabs.com米国で薬物、アルコール、DNA、臨床検査、スクリーニングサービスを提供するフランチャイズシステムを提供。ARCpoint FranchiseとAFG Servicesの2つのセグメントで事業を展開。臨床医療、インフルエンザ、連鎖球菌、コビドなどのウイルス検査、規制遵守検査、病気検査、毎年の健康、心臓の健康、甲状腺、糖尿病、ホルモン検査とスクリーニングを含む予防医療サービス、食物アレルギー/過敏症、ビタミン/栄養素欠乏症検査からなる栄養検査、結核や力価、妊娠、呼吸器、血液型検査サービス、ワクチン、ビタミン、サプリメント注射などの特殊健康ソリューションを提供している。また、薬物、アルコール、EtG、マリファナ、PEth、未知物質、現場での移動検査、父子関係やDNAサービス、性病、ドライアイ検査サービスも提供している。さらに、DOTソリューション、バックグラウンド・スクリーニング、HR雇用ソリューション、企業ウェルネス・プログラムからなる雇用者向けソリューションも提供している。さらに、マーケティング、テクノロジー、トレーニングサービスも提供している。個人、企業、法律・医療専門家にサービスを提供している。以前はRSIインターナショナル・システムズ社として知られていた。は1998年に設立され、サウスカロライナ州グリーンビルに本社を置いている。もっと見るARCpoint Inc. 基礎のまとめARCpoint の収益と売上を時価総額と比較するとどうか。ARC 基礎統計学時価総額CA$1.28m収益（TTM）-CA$2.92m売上高(TTM)CA$836.76k1.5xP/Sレシオ-0.4xPER（株価収益率ARC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ARC 損益計算書（TTM）収益US$605.71k売上原価US$97.66k売上総利益US$508.05kその他の費用US$2.62m収益-US$2.12m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.016グロス・マージン83.88%純利益率-349.32%有利子負債／自己資本比率-108.8%ARC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 16:14終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ARCpoint Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.
Reported Earnings • Mar 05Full year 2025 earnings released: US$0.017 loss per share (vs US$0.013 profit in FY 2024)Full year 2025 results: US$0.017 loss per share (down from US$0.013 profit in FY 2024). Revenue: US$605.7k (down 89% from FY 2024). Net loss: US$2.12m (down 256% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.3m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-US$7.5m). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (CA$1.28m market cap, or US$918.6k). Minor Risk Revenue is less than US$5m (US$1.5m revenue).
Reported Earnings • Nov 30Third quarter 2025 earnings released: US$0.004 loss per share (vs US$0.051 profit in 3Q 2024)Third quarter 2025 results: US$0.004 loss per share (down from US$0.051 profit in 3Q 2024). Revenue: US$113.7k (down 91% from 3Q 2024). Net loss: US$507.2k (down 110% from profit in 3Q 2024).
Reported Earnings • Aug 27Second quarter 2025 earnings released: US$0.006 loss per share (vs US$0.015 loss in 2Q 2024)Second quarter 2025 results: US$0.006 loss per share (improved from US$0.015 loss in 2Q 2024). Net loss: US$704.2k (loss narrowed 50% from 2Q 2024).
お知らせ • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.
お知らせ • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.
Reported Earnings • Mar 05Full year 2025 earnings released: US$0.017 loss per share (vs US$0.013 profit in FY 2024)Full year 2025 results: US$0.017 loss per share (down from US$0.013 profit in FY 2024). Revenue: US$605.7k (down 89% from FY 2024). Net loss: US$2.12m (down 256% from profit in FY 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.3m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-US$7.5m). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (CA$1.28m market cap, or US$918.6k). Minor Risk Revenue is less than US$5m (US$1.5m revenue).
Reported Earnings • Nov 30Third quarter 2025 earnings released: US$0.004 loss per share (vs US$0.051 profit in 3Q 2024)Third quarter 2025 results: US$0.004 loss per share (down from US$0.051 profit in 3Q 2024). Revenue: US$113.7k (down 91% from 3Q 2024). Net loss: US$507.2k (down 110% from profit in 3Q 2024).
Reported Earnings • Aug 27Second quarter 2025 earnings released: US$0.006 loss per share (vs US$0.015 loss in 2Q 2024)Second quarter 2025 results: US$0.006 loss per share (improved from US$0.015 loss in 2Q 2024). Net loss: US$704.2k (loss narrowed 50% from 2Q 2024).
お知らせ • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.
Reported Earnings • May 28First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: US$177.4k (down 89% from 1Q 2024). Net loss: US$633.5k (loss narrowed 57% from 1Q 2024).
New Risk • May 08New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Negative equity (-US$6.6m). Market cap is less than US$10m (CA$11.6m market cap, or US$8.37m). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (26% increase in shares outstanding).
お知らせ • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.
お知らせ • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (50% average weekly change). Negative equity (-US$6.1m). Earnings have declined by 65% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (CA$9.43m market cap, or US$6.58m).
お知らせ • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.
Reported Earnings • Nov 29Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.016 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.051 (up from US$0.016 loss in 3Q 2023). Revenue: US$1.22m (down 24% from 3Q 2023). Net income: US$5.19m (up US$6.64m from 3Q 2023).
Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: US$1.65m (up 8.8% from 2Q 2023). Net loss: US$1.40m (loss narrowed 40% from 2Q 2023).
お知らせ • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.
お知らせ • Jul 06ARCpoint Inc. announced that it expects to receive CAD 1.5 million in fundingARCpoint Inc. announced a non-brokered private placement to issue up to 20,000,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,500,000 on July 5, 2024. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange.
Reported Earnings • Apr 30Full year 2023 earnings releasedFull year 2023 results: Revenue: US$6.67m (down 39% from FY 2022). Net loss: US$8.66m (loss widened 7.7% from FY 2022).
Board Change • Mar 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Roger He was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Jan 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$7.2m). Revenue has declined by 60% over the past year. Market cap is less than US$10m (CA$11.0m market cap, or US$8.18m). Minor Risk Shareholders have been diluted in the past year (12% increase in shares outstanding).
お知らせ • Jan 23ARCpoint Inc. announced that it has received $1.1 million in fundingOn January 22, 2024, ARCpoint Inc. closed the transaction. The company has now issued 11,000,000 Class A subordinate voting shares at a price of $0.10 per share for the gross proceeds of $1,100,000. Certain insiders of the company purchased or acquired direction or control over a total of 4,000,000 shares as part of the Offering.
お知らせ • Jan 04ARCpoint Inc. announced that it expects to receive $1.6 million in fundingARCpoint Inc. announced a non-brokered private placement of up to 16,000,000 subordinated voting common shares at a price of $0.10 per share for the gross proceeds of $1,600,000 on January 2, 2024. The company anticipates that certain directors, officers and insiders of the company will purchase shares in an aggregate amount of up to $450,000 under the offering, The offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.
Reported Earnings • Nov 24Third quarter 2023 earnings released: US$0.016 loss per share (vs US$11.81 loss in 3Q 2022)Third quarter 2023 results: US$0.016 loss per share (improved from US$11.81 loss in 3Q 2022). Revenue: US$1.61m (down 5.8% from 3Q 2022). Net loss: US$1.45m (loss narrowed 18% from 3Q 2022).
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.026 loss per share (vs US$6.90 loss in 2Q 2022)Second quarter 2023 results: US$0.026 loss per share. Revenue: US$1.52m (down 33% from 2Q 2022). Net loss: US$2.34m (loss widened 127% from 2Q 2022).
お知らせ • Jul 12Arcpoint Inc. Launches MyARCpointLabsARCpoint Inc. reported that it has launched its new consumer e-commerce platform, MyARCpointLabs. MyARCpointLabs was developed to make it easier for both the Company's franchisees to attract and better serve individual healthcare consumers and for consumers to more easily purchase the Company's products and services. ARCpoint's goal is to leverage technology along with brick-and-mortar locations to give consumers access to convenient, cost-effective healthcare information and solutions with transparent, up-front pricing, so that they can be proactive and preventative with their health and well-being. By combining an easy-to-use consumer mobile platform with intuitive digital marketing and scheduling tools, MAPL will help close a growing gap within the healthcare system by delivering preventative healthcare solutions to all those who want them.
Reported Earnings • May 20First quarter 2023 earnings released: US$0.023 loss per share (vs US$4.64 profit in 1Q 2022)First quarter 2023 results: US$0.023 loss per share (down from US$4.64 profit in 1Q 2022). Revenue: US$1.71m (down 69% from 1Q 2022). Net loss: US$2.03m (down 393% from profit in 1Q 2022).
お知らせ • May 16Arcpoint Inc. Announces Appointment of Mr. Bob Mann as President of Arcpoint FranchiseARCpoint Inc. announced that Mr. Bob Mann has been appointed President of ARCpoint Franchise Group LLC (AFG), a wholly owned US subsidiary of the Company that operates ARCpoints franchise business. Mr. Mann comes to AFG with over 20 years of successful leadership and innovation experience including 15 years in the US diagnostic services space. He will be responsible for driving both top line growth at all franchisee locationsand growing the Companys distribution network from the current 134 locations. Mr. Mann started his diagnostics career at Quest Diagnostics in 2006 as a Sales Manager for Quests NC and SC sales teams before taking on different roles including: leading new business acquisition, developing strategiesfor growth and working with health plans and large healthcare entities. In 2012, he joined Cordant Health Solutions, then known as Sterling Healthcare, which went on to acquire five laboratories and six pharmacies to grow into one of the leading toxicology labs and behavioral health pharmacies in the US. For the past 8 years, Mr. Mann served as part of Cordants Executive Leadership team and held several key roles, including as Executive Vice President of Cordants Integrated Services group and overseeing sales and strategy. He was instrumental in the development of many of Cordants strategic toxicology and pharmacy offerings and also led the development of Cordants novel behavioral health pharmacy program that integrated laboratory and pharmacy services.
Reported Earnings • Apr 15Full year 2022 earnings released: US$0.10 loss per share (vs US$38.48 profit in FY 2021)Full year 2022 results: US$0.10 loss per share (down from US$38.48 profit in FY 2021). Revenue: US$10.9m (down 43% from FY 2021). Net loss: US$8.04m (down 240% from profit in FY 2021).
Buying Opportunity • Dec 10Now 31% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be CA$0.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
お知らせ • Nov 16+ 1 more updateARCpoint Inc. to Report Q3, 2022 Results on Nov 28, 2022ARCpoint Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 28, 2022
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Mark Orsmond was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
